News Room

News

"BeyondDx" to Present Tumor Analysis Platform Research Results at ASCO in May

2024-04-16 10:35:13

http://www.hitnews.co.kr/news/articleView.html?idxno=54006  

 

 

BeyondDx to Present Research Results of Tumor Analysis Platform at ASCO in May

Presentation of a Predictive Model for Treatment Responsiveness through Cancer Prognosis Monitoring and Analysis of Metastasis Patterns 




(Fig. 
Overview of Early Lung Cancer Metastasis Profiling with DXGate TO)

 

 

BeyondDx (CEO: Jung Sojin) announced on the 11th that it will present the clinical results targeting early lung cancer using its tumor profiling platform technology 'iDXGate TO' at the American Society of Clinical Oncology (ASCO) in May.

 

iDXGate TO is a platform that analyzes gene patterns by applying multiple biomarkers to circulating tumor cells in the blood of cancer patients, capturing cells with high purity and efficiency. The company has completed the domestic patent application for the 'Any-Hold technique,' which increases the sensitivity of antibody sets and the ability to capture target cells by more than five times. In addition, the company plans to develop iDXGate TO into a final in vitro diagnostic medical device form.

 

According to the company, the research results to be presented at ASCO in May compare the profiling results of circulating tumor cells, circulating tumor DNA, and primary tumor in the blood of resectable early lung cancer patients. The study was conducted with blood and primary tumor tissues obtained from 50 stage I-II lung cancer patients.

 

A company official stated, "Metastasis, where cancer cells spread from the primary tumor to distant organs, is an important factor affecting patient prognosis and treatment outcomes. Understanding the metastatic patterns leads to effective treatment strategies and influences patient survival rates." They added, "Through this research, we can now monitor metastatic patterns clearly distinguished from early primary lung cancer in real-time and confirm treatment responses. We plan to secure patterns of remote metastatic spread and resistance/recurrence patterns according to treatment therapies through further research."